Blood Pressure Reduction and Secondary Stroke Prevention

Hypertension

Volumn 69, Issue 1, 2017, Pages 171-179

  Katsanos, Aristeidis H ^a,c   Filippatou, Angeliki ^a   Manios, Efstathios ^a   Deftereos, Spyridon ^a,b   Parissis, John ^a,b   Frogoudaki, Alexandra ^a,b   Vrettou, Agathi Rosa ^a,b   Ikonomidis, Ignatios ^a,b   Pikilidou, Maria ^d   Kargiotis, Odysseas ^e   Voumvourakis, Konstantinos ^a   Alexandrov, Anne W ^f   Alexandrov, Andrei V ^f,g   Tsivgoulis, Georgios ^a,f,h  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

^e METROPOLITAN HOSPITAL   (Greece)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^h ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

antihypertensive agents; blood pressure; meta analysis; regression analysis; stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO; ANTIDIABETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; DIASTOLIC BLOOD PRESSURE; DISABILITY; FATALITY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NORMAL VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SCOPUS; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; COMPLICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STROKE;

BLOOD PRESSURE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; STROKE;

EID: 84994126479     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08485     Document Type: Review

References (38)

1. Steiner T, Al-Shahi Salman R, Beer R, et al; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9:840-855. doi: 10.1111/ijs.12309.
2. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.
3. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480. doi: 10.1016/S1474-4422(10)70066-1.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741-2748. doi: 10.1161/01.STR.0000092488.40085.15.
5. Castilla-Guerra L, Fernández-Moreno Mdel C. Update on the management of hypertension for secondary stroke prevention. Eur Neurol. 2012;68:1-7. doi: 10.1159/000336836.
6. Boan AD, Lackland DT, Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke. 2014;45:2506-2513. doi: 10.1161/ STROKEAHA.114.003666.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34. doi: 10.1016/j.jclinepi.2009.06.006.
8. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
9. Tsivgoulis G, Katsanos AH, Butcher KS, Boviatsis E, Triantafyllou N, Rizos I, Alexandrov AV. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-1529. doi: 10.1212/WNL.0000000000000917.
10. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Website. 2011. http://handbook.cochrane.org/chapter-9/9-analysing-data- and-undertaking-meta-analyses.htm. Accessed February 4, 2014.
11. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. doi: 10.1136/bmj.315.7109.629.
13. Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, Hankey GJ, Howes FS, Leckie L, Perkovic V, Schlaich M, Zwar NA, Medley TL, Arnolda L. Guideline for the diagnosis and management of hypertension in adults-2016. Med J Aust. 2016;205:85-89. doi: 10.5694/mja16.00526.
14. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Chapter 19: Subgroup analyses. Introduction to Meta-Analysis. Chichester, United Kingdom: John Wiley &Sons Ltd. doi: 10.1002/9780470743386.ch19.
15. Deeks JJ, Higgins JP, Altman DG. Chapter 9.6.4: Meta-regression. Cochrane Handbook for Systematic Reviews of Interventions Website. 2011. http://handbook.cochrane.org/chapter-9/9-6-4-meta-regression. htm. Accessed July 4, 2016
16. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489. doi: 10.1016/S0140-6736(70)91577-1.
17. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke. 1993;24:543-548. doi: 10.1161/01.STR.24.4.543.
18. Eriksson S, Olofsson BO, Wester PO, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5:21-25. doi: 10.1159/000107813.
19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153. doi: 10.1056/ NEJM200001203420301.
20. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974; 229:409-418. doi: 10.1001/ jama.1974.03230420021019.
21. Liu LS, Gong LS, Wang W; Blood Pressure Lowering to Prevent Recurrent Stroke Study Group. [Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases-A large-scale, randomized, placebo controlled trial]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:613-617. doi: 10.3760/j:issn:0253-3758.2005.07.008.
22. Martí Massó JF, Lozano R. Nicardipine in the prevention of cerebral infarction. Clin Ther. 1990;12:344-351.
23. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226. doi: 10.1161/01. STR.0000166048.35740.a9.
24. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, Virdee S, Greenfield S, Hobbs FD. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke-Blood Pressure) randomised controlled trial. BMJ. 2016;352:i708.
25. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710-717.
26. Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237. doi: 10.1056/NEJMoa0804593.
27. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041. doi: 10.1016/S0140-6736(01)06178-5.
28. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886. doi: 10.1097/01.hjh.0000059028.82022.89.
29. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-515. doi: 10.1016/S0140-6736(13)60852-1.
30. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58:113-130.
31. Sacco RL, Kasner SE, Broderick JP, et al; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064-2089. doi: 10.1161/STR.0b013e318296aeca.
32. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-443. doi: 10.1016/S0140-6736(15)00805-3.
33. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. doi: 10.1093/eurheartj/eht151.
34. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
35. Rosendorff C, Lackland DT, Allison M, et al; American Heart Association; American College of Cardiology; American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65:1998-2038. doi: 10.1016/j.jacc.2015.02.038.
36. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116. doi: 10.1056/ NEJMoa1511939.
37. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-1043. doi: 10.1056/NEJMoa1603460.
38. Wang WT, You LK, Chiang CE, Sung SH, Chuang SY, Cheng HM, Chen CH. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials. Medicine (Baltimore). 2016;95:e3302. doi: 10.1097/MD.0000000000003302.